2 Mar 2021 12:38
REDX PHARMA PLC
("Redx" or "the Company")
Result of Annual General Meeting and Directorate change
Alderley Park, 2 March 2021 Redx Pharma (AIM:REDX), the drug discovery and development Company focused on oncology and fibrosis, today announces that its Annual General Meeting was held at 11.00 am on 2 March 2021, with all resolutions passed by substantial majorities.
The table below sets out the details of the votes put to shareholders
Resolution numbe | Resolution name | Number of votes for & discretionary | % of votes for & discretionary | Number of votes against | % of votes against | % of votes witheld | Total votes cast (including withheld) |
1 | Receive the Company's annual accounts | 247,031,884 | 94.79% | 13,571,429 | 5.21% | 0.00% | 260,604,013 |
2 | Re-appoint RSM as auditors | 260,597,840 | 100% | 200 | 0.00% | 0.00% | 260,604,013 |
3 | Elect Sarah Gordon Wild as a director | 260,597,840 | 100% | 200 | 0.00% | 0.00% | 260,604,013 |
4 | Elect Dr Thomas Burt as a director | 260,597,840 | 100% | 200 | 0.00% | 0.00% | 260,604,013 |
5 | Re-elect Lisa Anson as a director | 260,603,513 | 100% | 0 | 0.00% | 0.00% | 260,604,013 |
6 | Re-elect Dr Bernd Kirschbaum as a director | 260,598,040 | 100% | 0 | 0.00% | 0.00% | 260,604,013 |
7 | Re-elect Peter Presland as a director | 260,603,513 | 100% | 0 | 0.00% | 0.00% | 260,604,013 |
8 | Authorise the directors to allot shares | 260,594,551 | 100% | 1,686 | 0.00% | 0.00% | 260,604,013 |
9 | Disapply pre-emption rights | 260,594,551 | 100% | 2,389 | 0.00% | 0.00% | 260,604,013 |
The Chairman, Iain Ross provided the following update:
"As the Company continues to progress its pipeline and expand its operations, the Board has reviewed its composition and that of the executive leadership team. As a result, a search for a US based Chief Financial Officer has been initiated. James Mead will continue in his role as Chief Financial Officer until a new appointment has been made at which point Dr Mead will assume the role of Chief Operating Officer. In conjunction with these changes, Dr Mead will step down from the Board with immediate effect and will cease to be a Director of the Company. Going forward, the Board will therefore consist of five non-executive directors and one executive director, the CEO. Finally on a personal basis I would like to thank James for his contribution to the Board over the last two years, and his ongoing commitment as a member of the executive management team going forward."
For further information, please contact: | |
Redx Pharma Plc | T: +44 1625 469 918 |
Iain Ross, Chairman Lisa Anson, Chief Executive James Mead, Chief Financial Officer | |
SPARK Advisory Partners (Nominated Adviser) | T: +44 203 368 3550 |
Matt Davis/Adam Dawes | |
WG Partners LLP (Broker) | T: +44 20 3705 9330 |
Claes Spång/Chris Lee/David Wilson | |
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Ciara Martin | |
|
About Redx Pharma Plc
Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx's lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.
The Company's core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).